1-20 of 4,312 results for subject:Cannabis
Librarians' tools
- Search time
- 0.333 seconds
- Solr query time
- 0.01 seconds
- Search query
- subject:Cannabis
- We searched for
- subject_t:Cannabis OR subject_t:Cannabidiol OR subject_t:Dronabinol OR subject_t:Epidiolex OR subject_t:Marijuana OR subject_t:Nabiximols OR subject_t:Sativex OR subject_t:Skunk OR subject_t:Tetrahydrocannabinol OR subject_t:THC OR subject_ses:8939
Type
House
Session
More
Year
More
Department
More
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
More
Subject
More
Publisher
To ask the Secretary of State for the Home Department, what her planned timetable is for the Advisory Council on the Misuse of Drugs to publish its review of cannabis-based products for medicinal use.
To ask the Secretary of State for the Home Department, what her planned timetable is for the Advisory Council on the Misuse of Drugs to publish its review of cannabis-based products for medicinal use.
The Government commissioned the Advisory Council on the Misuse of Drugs (‘ACMD’) to review the current evidence on cannabis-based products for medicinal use (‘CBPMs’) on 2 June 2025.
The ACMD is an independent scientific advisory body and determines its own procedures. In its Work Programme, published on 21 September 2026, the ACMD has said that it expects to publish the report on CBPMs by the end of the year.
To ask His Majesty's Government what plans they have to ask the Advisory Council on the Misuse of Drugs to review the classification of cannabis in light of new evidence on the effects of the drug on mental and physical health which has come to light since the Council last...
To ask His Majesty's Government what plans they have to ask the Advisory Council on the Misuse of Drugs to review the classification of cannabis in light of new evidence on the effects of the drug on mental and physical health which has come to light since the Council last...
Cannabis is controlled as a Class B drug under the Misuse of Drugs Act 1971.
Ministers have a statutory obligation to receive and consider advice from the Advisory Council on the Misuse of Drugs (‘ACMD’) before seeking to make changes to the classification of drugs through secondary legislation.
The Government has no current plans to commission the ACMD to re-assess the classification of cannabis under the Misuse of Drugs Act 1971.
To ask the Secretary of State for the Home Department, what guidance her Department provides to police forces on working with social landlords and local authorities to address repeated reports of cannabis use causing anti-social behaviour at residential properties.
To ask the Secretary of State for the Home Department, what guidance her Department provides to police forces on working with social landlords and local authorities to address repeated reports of cannabis use causing anti-social behaviour at residential properties.
Cannabis is controlled as a Class B drug under the Misuse of Drugs Act 1971, the maximum penalty for possession is up to five years in prison, an unlimited fine, or both; and the maximum penalty for supply and production is up to 14 years in prison, an unlimited fine, or both. Policing of cannabis offences is an operational matter for police forces, and we expect them to enforce the law.
On 6 October, we published updated ASB statutory guidance ahead of commencement of the provisions in the Crime and Policing Act 2026 on 26 October. The guidance will provide frontline practitioners clarity on the new powers and processes coming into force on 26 October, helping police, councils, housing providers and courts implement the reforms consistently and effectively. This includes powers that may be used to address persistent anti-social behaviour linked to issues such as drug-related nuisance, where the relevant legal tests are met.
To ask the Secretary of State for the Home Department, what guidance her Department provides to police forces on the evidential threshold for taking enforcement action following repeated reports of cannabis use at residential properties.
To ask the Secretary of State for the Home Department, what guidance her Department provides to police forces on the evidential threshold for taking enforcement action following repeated reports of cannabis use at residential properties.
Cannabis is controlled as a Class B drug under the Misuse of Drugs Act 1971, the maximum penalty for possession is up to five years in prison, an unlimited fine, or both; and the maximum penalty for supply and production is up to 14 years in prison, an unlimited fine, or both. Policing of cannabis offences is an operational matter for police forces, and we expect them to enforce the law.
On 6 October, we published updated ASB statutory guidance ahead of commencement of the provisions in the Crime and Policing Act 2026 on 26 October. The guidance will provide frontline practitioners clarity on the new powers and processes coming into force on 26 October, helping police, councils, housing providers and courts implement the reforms consistently and effectively. This includes powers that may be used to address persistent anti-social behaviour linked to issues such as drug-related nuisance, where the relevant legal tests are met.
To ask His Majesty's Government, in light of the Advisory Council on the Misuse of Drugs’ 2026 work programme, published on 11 March, which stated that its review of cannabis-based products for medicinal use was expected to be completed by summer 2026, (1) what discussions they have had with the Council...
To ask His Majesty's Government, in light of the Advisory Council on the Misuse of Drugs’ 2026 work programme, published on 11 March, which stated that its review of cannabis-based products for medicinal use was expected to be completed by summer 2026, (1) what discussions they have had with the Council...
I am grateful that the Department has moved swiftly to identify the issues with the supply of Bedrolite from Bedrocan, the company in real difficulty in the Netherlands. I understand that there is confidence in supplies until 2027, but my constituents say that that may depend on whether someone has an NHS or a private prescription. Would the Minister and his officials meet me to go through these processes, some of which, from my constituents’ experience, have been very bureaucratic?
I am grateful that the Department has moved swiftly to identify the issues with the supply of Bedrolite from Bedrocan, the company in real difficulty in the Netherlands. I understand that there is confidence in supplies until 2027, but my constituents say that that may depend on whether someone has an NHS or a private prescription. Would the Minister and his officials meet me to go through these processes, some of which, from my constituents’ experience, have been very bureaucratic?
My hon. Friend makes a really important point. Ensuring sustainable supply for so sensitive a medicine to address epilepsy is uppermost in my mind. It is a live situation, I am working at pace with officials, and I will update her accordingly.
My hon. Friend makes a really important point. Ensuring sustainable supply for so sensitive a medicine to address epilepsy is uppermost in my mind. It is a live situation, I am working at pace with officials, and I will update her accordingly.
To ask the Secretary of State for Health and Social Care, if she will take diplomatic and regulatory steps with the Dutch Ministry of Health and the Medicines and Healthcare products Regulatory Agency (MHRA) to secure the emergency export release of existing Bedrolite stockpiles following the insolvency of Bedrocan; and...
To ask the Secretary of State for Health and Social Care, if she will take diplomatic and regulatory steps with the Dutch Ministry of Health and the Medicines and Healthcare products Regulatory Agency (MHRA) to secure the emergency export release of existing Bedrolite stockpiles following the insolvency of Bedrocan; and...
The British Embassy in The Hague is in contact with the Dutch Ministry of Health, Welfare and Sport to understand the reported changes affecting Bedrocan products and the potential impact on United Kingdom patients who currently rely on them.
Clinical decisions regarding an individual patient are a matter for their responsible clinician, who are best placed to assess and manage patient risk.
To ask His Majesty's Government whether they intend to seek an urgent agreement with the government of the Netherlands, similar to the arrangement made in 2021 for patients with NHS prescriptions, to ensure that patients with private prescriptions do not lose access to Bedrolite as treatment for their epileptic seizures.
To ask His Majesty's Government whether they intend to seek an urgent agreement with the government of the Netherlands, similar to the arrangement made in 2021 for patients with NHS prescriptions, to ensure that patients with private prescriptions do not lose access to Bedrolite as treatment for their epileptic seizures.
The British Embassy in The Hague is in contact with the Dutch Ministry of Health, Welfare and Sport to understand the reported changes affecting the manufacturer of Bedrolite and the potential impact on UK-based patients who currently rely on this product.
The Government recognises the importance of uninterrupted access to medicines for patients, but clinical decisions regarding an individual patient will remain a matter for their responsible clinicians, who are best placed to assess and manage patient risk.
To ask His Majesty's Government what urgent action they plan to take, in consultation with the government of the Netherlands, to secure continued supplies of Bedrolite for patients with severe epilepsy for whom it is the only effective treatment.
To ask His Majesty's Government what urgent action they plan to take, in consultation with the government of the Netherlands, to secure continued supplies of Bedrolite for patients with severe epilepsy for whom it is the only effective treatment.
The British Embassy in The Hague is in contact with the Dutch Ministry of Health, Welfare and Sport to understand the reported changes affecting the manufacturer of Bedrolite and the potential impact on UK-based patients who currently rely on this product.
The Government recognises the importance of uninterrupted access to medicines for patients, but clinical decisions regarding an individual patient will remain a matter for their responsible clinicians, who are best placed to assess and manage patient risk.
Bedrolite is a medication for those with a very rare form of epilepsy. There are, I understand, four private prescriptions and three NHS prescriptions in the country. It is made by a company based in the Netherlands called Bedrocan, which was in the news at the weekend because it is...
Bedrolite is a medication for those with a very rare form of epilepsy. There are, I understand, four private prescriptions and three NHS prescriptions in the country. It is made by a company based in the Netherlands called Bedrocan, which was in the news at the weekend because it is...
This is a really serious matter, and my hon. Friend is right to bring it to the Floor of the House, because it is of huge concern to the families affected. She said that she had written to the Secretary of State and the relevant Minister. I am not sure...
This is a really serious matter, and my hon. Friend is right to bring it to the Floor of the House, because it is of huge concern to the families affected. She said that she had written to the Secretary of State and the relevant Minister. I am not sure...
To ask the Secretary of State for Health and Social Care, whether she considers the volume of prescriptions issued for cannabis-based products for medicinal use to be consistent with patient safety.
To ask the Secretary of State for Health and Social Care, whether she considers the volume of prescriptions issued for cannabis-based products for medicinal use to be consistent with patient safety.
I refer the Hon Member to the answer provided on 1 June in response to Question 3220.
To ask the Secretary of State for Health and Social Care, what steps her Department and the MHRA are taking to enforce restrictions on the advertising of cannabis-based products for medicinal use on social media.
To ask the Secretary of State for Health and Social Care, what steps her Department and the MHRA are taking to enforce restrictions on the advertising of cannabis-based products for medicinal use on social media.
I refer the Hon Member to the answer provided on 1 June in response to Question 3220.
To ask the Secretary of State for Health and Social Care, how many patients with multiple sclerosis were prescribed nabiximols on the NHS in England in each of the last three years by integrated care board.
To ask the Secretary of State for Health and Social Care, how many patients with multiple sclerosis were prescribed nabiximols on the NHS in England in each of the last three years by integrated care board.
Nabiximols is the United States Adopted Name for the medication marketed as Sativex (dronabinol/cannabidiol) and licensed by the Medicines and Healthcare products Regulatory Agency for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis.
The attached table shows the number of identifiable patients who were prescribed Sativex in the community in England by integrated care board in each financial year from 2023 to 2026 and from April 2026 to June 2026. The NHS Business Services Authority does not hold information on patient condition or reasons for why Sativex has been prescribed.
The Department has made no assessment of the levels of variation in access to Sativex for multiple-sclerosis related spasticity. National Health Service commissioners are expected to take National Institute for Health and Care Excellence (NICE) guidelines fully into account in ensuring that services meet the needs of their local populations. NICE keeps its guidelines under review and would consider the need to update its recommendations on Sativex in light of any new evidence.
To ask the Secretary of State for Health and Social Care, what assessment her Department has made of trends in the level of regional variation in access to nabiximols for MS-related spasticity since NICE guideline NG144 was published.
To ask the Secretary of State for Health and Social Care, what assessment her Department has made of trends in the level of regional variation in access to nabiximols for MS-related spasticity since NICE guideline NG144 was published.
Nabiximols is the United States Adopted Name for the medication marketed as Sativex (dronabinol/cannabidiol) and licensed by the Medicines and Healthcare products Regulatory Agency for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis.
The attached table shows the number of identifiable patients who were prescribed Sativex in the community in England by integrated care board in each financial year from 2023 to 2026 and from April 2026 to June 2026. The NHS Business Services Authority does not hold information on patient condition or reasons for why Sativex has been prescribed.
The Department has made no assessment of the levels of variation in access to Sativex for multiple-sclerosis related spasticity. National Health Service commissioners are expected to take National Institute for Health and Care Excellence (NICE) guidelines fully into account in ensuring that services meet the needs of their local populations. NICE keeps its guidelines under review and would consider the need to update its recommendations on Sativex in light of any new evidence.
To ask the Secretary of State for Health and Social Care, what steps she is taking to ensure integrated care boards commission nabiximols in line with NICE guideline NG144.
To ask the Secretary of State for Health and Social Care, what steps she is taking to ensure integrated care boards commission nabiximols in line with NICE guideline NG144.
Nabiximols is the United States Adopted Name for the medication marketed as Sativex (dronabinol/cannabidiol) and licensed by the Medicines and Healthcare products Regulatory Agency for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis.
The attached table shows the number of identifiable patients who were prescribed Sativex in the community in England by integrated care board in each financial year from 2023 to 2026 and from April 2026 to June 2026. The NHS Business Services Authority does not hold information on patient condition or reasons for why Sativex has been prescribed.
The Department has made no assessment of the levels of variation in access to Sativex for multiple-sclerosis related spasticity. National Health Service commissioners are expected to take National Institute for Health and Care Excellence (NICE) guidelines fully into account in ensuring that services meet the needs of their local populations. NICE keeps its guidelines under review and would consider the need to update its recommendations on Sativex in light of any new evidence.
To ask the Secretary of State for Health and Social Care, whether she has asked NICE to review the position of nabiximols in the treatment pathway for MS-related spasticity, including its use earlier in the pathway.
To ask the Secretary of State for Health and Social Care, whether she has asked NICE to review the position of nabiximols in the treatment pathway for MS-related spasticity, including its use earlier in the pathway.
Nabiximols is the United States Adopted Name for the medication marketed as Sativex (dronabinol/cannabidiol) and licensed by the Medicines and Healthcare products Regulatory Agency for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis.
The attached table shows the number of identifiable patients who were prescribed Sativex in the community in England by integrated care board in each financial year from 2023 to 2026 and from April 2026 to June 2026. The NHS Business Services Authority does not hold information on patient condition or reasons for why Sativex has been prescribed.
The Department has made no assessment of the levels of variation in access to Sativex for multiple-sclerosis related spasticity. National Health Service commissioners are expected to take National Institute for Health and Care Excellence (NICE) guidelines fully into account in ensuring that services meet the needs of their local populations. NICE keeps its guidelines under review and would consider the need to update its recommendations on Sativex in light of any new evidence.
To ask the Secretary of State for the Home Department, if her Department will commission a review of the potential impact of cannabis decriminalisation and legalisation abroad on levels of crime and anti-social behaviour in the UK.
To ask the Secretary of State for the Home Department, if her Department will commission a review of the potential impact of cannabis decriminalisation and legalisation abroad on levels of crime and anti-social behaviour in the UK.
There are no current plans to commission a review of the potential impact of cannabis decriminalisation and legalisation abroad on levels of crime and anti-social behaviour (‘ASB’) in the UK.
The Government recognises the clear scientific evidence of the harms of cannabis and has no plans to change the law. Cannabis is an addictive substance and is controlled as a Class B drug.
The Advisory Council on the Misuse of Drugs (‘ACMD’), the Government’s independent advisory body on drugs, has previously commented that the use of cannabis is a significant public health issue and can unquestionably cause harm to individuals and society. The ACMD considered the question of cannabis harms most recently in its 2018 contribution to the work on policy relating to cannabis-based products for medicinal use.
We are working closely with partners overseas in source and transit countries to stem the supply of drugs into the UK, as part of an overall approach including law enforcement activity, investment in drug treatment and recovery, and prevention to reduce demand, in order to minimise crime and ASB on our streets.
To ask the Secretary of State for the Home Department, whether her Department has considered permitting individuals holding a valid prescription for a cannabis-based product for medicinal use to apply for a licence to cultivate cannabis for their own prescribed use.
To ask the Secretary of State for the Home Department, whether her Department has considered permitting individuals holding a valid prescription for a cannabis-based product for medicinal use to apply for a licence to cultivate cannabis for their own prescribed use.
Cannabis-based products for medicinal use may be lawfully possessed where they have been prescribed by an appropriately qualified clinician. However, a prescription does not authorise the cultivation of cannabis.
Cannabis may only be cultivated under a Home Office licence. The Government has no plans to change the existing licensing arrangements to permit individuals to cultivate cannabis for their own prescribed use. Licences for the cultivation of high-THC cannabis may be issued for lawful purposes, including the production of pharmaceutical products, subject to compliance with the relevant medicines regulatory requirements.